首页> 外文会议>Conference on Lasers and Electro-Optics >Determining Metabolic Changes Associated with Tamoxifen Treatment and Resistance in Breast Cancer

【24h】

Determining Metabolic Changes Associated with Tamoxifen Treatment and Resistance in Breast Cancer

机译：测定与他莫昔芬治疗和耐药相关的代谢变化

获取原文

页面导航

摘要
著录项
相似文献
相关主题

摘要

Autofluorescence lifetimes of endogenous NAD(P)H are altered when breast cancer cells are treated with tamoxifen and is distinguishable when comparing tamoxifen sensitive and resistant breast cancer cells.

机译：当用他莫昔芬治疗乳腺癌细胞时，内源性NAD（P）H的自发荧光寿命会发生改变，并且在比较他莫昔芬敏感和耐药的乳腺癌细胞时可区分。

著录项

来源
《Conference on Lasers and Electro-Optics》|2019年|1-2|共2页
会议地点
作者
David Rodriguez; Yan Zheng; Kevin D. Houston; Jessica P. Houston;
展开▼
作者单位

展开▼
会议组织
原文格式 PDF
正文语种
中图分类
关键词
cancer; cellular biophysics; drug delivery systems; fluorescence; tumours;

机译：癌症;细胞生物物理学;药物输送系统;荧光;肿瘤;

相似文献

外文文献
中文文献
专利

1. STAT3 mediates resistance of CD44~＋CD24~（-/low） breast cancer stem cells to tamoxifen in vitroSTAT3 mediates resistance of CD44~＋CD24~（-/low） breast cancer stem cells to tamoxifen in vitroSTAT3 mediates resistance of CD44＋CD24（-/low） breast cancer stem cells to tamoxifen in vitro [J] . Xiaoyan Wang, Guozhu Wang, Yi Zhao, 生物医学研究杂志：英文版 . 2012,第005期

机译：STAT3介导CD44〜＋ CD24〜（-/ low）乳腺癌干细胞对他莫昔芬的抗性STAT3介导CD44〜＋ CD24〜（-/ low）乳腺癌干细胞对他莫昔芬的抗性乳腺癌干细胞体外他莫昔芬
2. Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment [J] . Karin Beelen, Mark Opdam, Tesa M Severson, Breast Cancer Research . 2014,第1期

机译：磷酸化的P-70S6K预测佐剂Tamoxifen与全身治疗之间随机化的绝经后乳腺癌患者中的他莫昔芬抗性
3. Muc1 -induced Alterations In A Lipid Metabolic Gene Network Predict Response Of Human Breast Cancers To Tamoxifen Treatment [J] . Sean P. Pitroda, Nikolai N. Khodarev, Michael A. Beckett, Proceedings of the National Academy of Sciences of the United States of America . 2009,第14期

机译：Muc1诱导的脂质代谢基因网络改变预测人类乳腺癌对他莫昔芬治疗的反应
4. Determining Metabolic Changes Associated with Tamoxifen Treatment and Resistance in Breast Cancer [C] . David Rodriguez, Yan Zheng, Kevin D. Houston, Conference on Lasers and Electro-Optics . 2019

机译：确定与乳腺癌治疗和抗性相关的代谢变化
5. G Protein-coupled Estrogen Receptor 1 (GPER1) and Insulin-like Growth Factor Binding Protein 1 (IGFBP-1) Are Key Components of Tamoxifen Action and the Development of Tamoxifen Resistance in Breast Cancer Cells [D] . Zheng, Yan. 2019

机译：G蛋白偶联雌激素受体1（GPER1）和胰岛素样生长因子结合蛋白1（IGFBP-1）是他莫昔芬作用的关键组分和乳腺癌细胞中他莫昔芬抗性的发育
6. Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment [O] . Karin Beelen, Mark Opdam, Tesa M Severson, 2014

机译：磷酸化的p-70S6K预测绝经后乳腺癌患者中的他莫昔芬耐药性随机分配为他莫昔芬辅助治疗与不接受全身治疗之间
7. Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment [O] . Karin Beelen, Mark Opdam, Tesa M Severson, 2014

机译：磷酸化的p-70S6K预测绝经后乳腺癌患者中的他莫昔芬耐药性随机分配为他莫昔芬辅助治疗与不接受全身治疗之间
8. Systematic Reviews on Selected Pharmacogenetic Tests for Cancer Treatment: CYP2D6 for Tamoxifen in Breast Cancer, KRAS for anti-EGFR antibodies in Colorectal Cancer, and BCR-ABL1 for Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Technology Assessment Report [R] . Terasawa, T., Dahabreh, I., Castaldi, P. J., 2010

机译：针对癌症治疗的选定药物遗传学测试的系统评价：CYp2D6用于乳腺癌中的他莫昔芬，KRas用于结肠直肠癌中的抗EGFR抗体，以及BCR-aBL1用于慢性髓性白血病中的酪氨酸激酶抑制剂。技术评估报告

Determining Metabolic Changes Associated with Tamoxifen Treatment and Resistance in Breast Cancer

摘要

著录项

相似文献

相关主题

期刊订阅